Relief Therapeutics Holding AG - Asset Resilience Ratio
Relief Therapeutics Holding AG (RLF) has an Asset Resilience Ratio of 0.01% as of December 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Relief Therapeutics Holding AG total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2023)
This chart shows how Relief Therapeutics Holding AG's Asset Resilience Ratio has changed over time. See Relief Therapeutics Holding AG (RLF) shareholders funds for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Relief Therapeutics Holding AG's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Relief Therapeutics Holding AG.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CHF0.00 | 0% |
| Short-term Investments | CHF9.00K | 0.01% |
| Total Liquid Assets | CHF9.00K | 0.01% |
Asset Resilience Insights
- Limited Liquidity: Relief Therapeutics Holding AG maintains only 0.01% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Relief Therapeutics Holding AG Industry Peers by Asset Resilience Ratio
Compare Relief Therapeutics Holding AG's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Relief Therapeutics Holding AG (2006–2023)
The table below shows the annual Asset Resilience Ratio data for Relief Therapeutics Holding AG.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 0.01% | CHF9.00K ≈ $11.38K |
CHF76.39 Million ≈ $96.58 Million |
0.00pp |
| 2022-12-31 | 0.01% | CHF28.00K ≈ $35.40K |
CHF188.80 Million ≈ $238.69 Million |
-- |
| 2021-12-31 | 0.00% | CHF0.00 ≈ $0.00 |
CHF251.62 Million ≈ $318.11 Million |
-- |
| 2020-12-31 | 0.24% | CHF185.00K ≈ $233.89K |
CHF78.05 Million ≈ $98.67 Million |
+0.18pp |
| 2013-12-31 | 0.06% | CHF25.73K ≈ $32.54K |
CHF45.98 Million ≈ $58.13 Million |
-18.38pp |
| 2006-12-31 | 18.43% | CHF14.15 Million ≈ $17.89 Million |
CHF76.76 Million ≈ $97.05 Million |
-- |
About Relief Therapeutics Holding AG
Relief Therapeutics Holding SA, a biopharmaceutical company, engages in identification, development, and commercialization of novel, patent protected products for the treatment of dermatological, metabolic, and pulmonary rare diseases. The company offers SETOFILM/ONDISSOLVE for nausea and vomiting associated with radiotherapy-induced, chemotherapy, and postoperative sequels; ACER-001, a sodium ph… Read more